Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma.

Gastric cancer Poorly cohesive sub-type Signet ring cell histology

Journal

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
ISSN: 1436-3305
Titre abrégé: Gastric Cancer
Pays: Japan
ID NLM: 100886238

Informations de publication

Date de publication:
01 2019
Historique:
received: 18 03 2018
accepted: 16 08 2018
pubmed: 1 9 2018
medline: 16 4 2019
entrez: 1 9 2018
Statut: ppublish

Résumé

Clinicopathological characteristics of gastric cancer (GC) are changing, especially in the West with a decreasing incidence of distal, intestinal-type tumours and the corresponding increasing proportion of tumours with Laurén diffuse or WHO poorly cohesive (PC) including signet ring cell (SRC) histology. To accurately assess the behaviour and the prognosis of these GC subtypes, the standardization of pathological definitions is needed. A multidisciplinary expert team belonging to the European Chapter of International Gastric Cancer Association (IGCA) identified 11 topics on pathological classifications used for PC and SRC GC. The topics were debated during a dedicated Workshop held in Verona in March 2017. Then, through a Delphi method, consensus statements for each topic were elaborated. A consensus was reached on the need to classify gastric carcinoma according to the most recent edition of the WHO classification which is currently WHO 2010. Moreover, to standardize the definition of SRC carcinomas, the proposal that only WHO PC carcinomas with more than 90% poorly cohesive cells having signet ring cell morphology have to be classified as SRC carcinomas was made. All other PC non-SRC types have to be further subdivided into PC carcinomas with SRC component (< 90% but > 10% SRCs) and PC carcinomas not otherwise specified (< 10% SRCs). The reported statements clarify some debated topics on pathological classifications used for PC and SRC GC. As such, this consensus classification would allow the generation of evidence on biological and prognostic differences between these GC subtypes.

Sections du résumé

BACKGROUND AND AIMS
Clinicopathological characteristics of gastric cancer (GC) are changing, especially in the West with a decreasing incidence of distal, intestinal-type tumours and the corresponding increasing proportion of tumours with Laurén diffuse or WHO poorly cohesive (PC) including signet ring cell (SRC) histology. To accurately assess the behaviour and the prognosis of these GC subtypes, the standardization of pathological definitions is needed.
METHODS
A multidisciplinary expert team belonging to the European Chapter of International Gastric Cancer Association (IGCA) identified 11 topics on pathological classifications used for PC and SRC GC. The topics were debated during a dedicated Workshop held in Verona in March 2017. Then, through a Delphi method, consensus statements for each topic were elaborated.
RESULTS
A consensus was reached on the need to classify gastric carcinoma according to the most recent edition of the WHO classification which is currently WHO 2010. Moreover, to standardize the definition of SRC carcinomas, the proposal that only WHO PC carcinomas with more than 90% poorly cohesive cells having signet ring cell morphology have to be classified as SRC carcinomas was made. All other PC non-SRC types have to be further subdivided into PC carcinomas with SRC component (< 90% but > 10% SRCs) and PC carcinomas not otherwise specified (< 10% SRCs).
CONCLUSION
The reported statements clarify some debated topics on pathological classifications used for PC and SRC GC. As such, this consensus classification would allow the generation of evidence on biological and prognostic differences between these GC subtypes.

Identifiants

pubmed: 30167905
doi: 10.1007/s10120-018-0868-0
pii: 10.1007/s10120-018-0868-0
doi:

Types de publication

Consensus Development Conference Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-9

Investigateurs

Baiocchi Gian Luca (BG)
Bencivenga Maria (B)
Flejou Jean-Francois (F)
Fumaglli Uberto (F)
Hoelscher Arnulf (H)
Iglesias Mar (I)
Marrelli Daniele (M)
Moenig Stephan (M)
Morgagni Paolo (M)
Pera Manuel (P)
Piessen Giullaume (P)
Reim Daniel (R)
Renaud Florence (R)
Roviello Franco (R)
Saragoni Luca (S)
Scarpa Aldo (S)
Schneider Paul (S)
Tomezzoli Anna (T)
Vieth Michael (V)
Wotherspoon Andrew (W)
Zamboni Giuseppe (Z)

Commentaires et corrections

Type : ErratumIn

Références

Cancer. 2003 Oct 1;98(7):1521-30
pubmed: 14508841
Arch Pathol Lab Med. 2004 Jul;128(7):765-70
pubmed: 15214826
Virchows Arch. 2008 May;452(5):525-34
pubmed: 18266006
Endoscopy. 2009 May;41(5):427-32
pubmed: 19418397
Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):1945-52
pubmed: 19531677
Ann Surg. 2009 Dec;250(6):878-87
pubmed: 19855261
Ann Surg Oncol. 2010 Dec;17(12):3187-94
pubmed: 20585867
Br J Surg. 2011 Sep;98(9):1273-83
pubmed: 21560122
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Ann Thorac Surg. 2011 Dec;92(6):2020-7
pubmed: 22115212
J Surg Oncol. 2012 Jun 15;105(8):800-4
pubmed: 22189799
J Clin Oncol. 2012 Oct 1;30(28):3493-8
pubmed: 22927530
J Clin Oncol. 2013 Jun 1;31(16):2059-60
pubmed: 23610107
Ann Surg Oncol. 2014 May;21(5):1678-85
pubmed: 24394986
Updates Surg. 2014 Mar;66(1):1-6
pubmed: 24523031
Gastric Cancer. 2015 Jul;18(3):618-26
pubmed: 24801199
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Ann Surg. 2014 Nov;260(5):779-84; discussion 784-5
pubmed: 25379849
Ann Thorac Surg. 2015 Jan;99(1):277-83
pubmed: 25442991
Gastric Cancer. 2016 Jan;19(1):15-20
pubmed: 26140915
Tumour Biol. 2016 Jan;37(1):709-14
pubmed: 26242270
Ann Surg. 2017 May;265(5):946-953
pubmed: 27232252
J Korean Med Sci. 2016 Jun;31(6):866-72
pubmed: 27247494
Ann Surg Oncol. 2016 Dec;23(Suppl 5):998-1004
pubmed: 27480358
Adv Exp Med Biol. 2016;908:371-91
pubmed: 27573781
Gastric Cancer. 2017 Jul;20(4):591-601
pubmed: 27858181
Semin Thorac Cardiovasc Surg. 2016 Summer;28(2):549-558
pubmed: 28043475
Ann Surg. 2017 Feb;265(2):356-362
pubmed: 28059964
Pathol Int. 2017 Aug;67(8):398-403
pubmed: 28691258
Histopathology. 2018 Mar;72(4):556-568
pubmed: 28873240
Hum Pathol. 1995 May;26(5):504-8
pubmed: 7750934
Cancer. 1994 Jun 1;73(11):2680-6
pubmed: 8194005
Cancer. 1993 May 15;71(10):2926-33
pubmed: 8490820
Am J Surg Pathol. 1996 May;20(5):588-98
pubmed: 8619423
Gen Diagn Pathol. 1997 Jul;143(1):39-48
pubmed: 9269907

Auteurs

C Mariette (C)

Department of Surgery, Hôpital Claude-Huriez, Lille, France.

F Carneiro (F)

Departments of Pathology, Centro Hospitalar São João, Faculty of Medicine of Porto University and Institute for Research and Innovation in Health (i3S), Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Porto, Portugal.

H I Grabsch (HI)

Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Pathology and Tumour Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.

R S van der Post (RS)

Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands.

W Allum (W)

Department of Upper Gastrointestinal Surgery, Royal Marsden Hospital, London, UK.

Giovanni de Manzoni (G)

General and Upper GI Surgery Division, Department of Surgery, University of Verona, Piazzale Stefani 1, 37126, Verona, Italy. giovanni.demanzoni@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH